Endothelial C/EBPβ/AEP pathway drives vascular deterioration and systemic aging.
Key claim: Progressive endothelial C/EBPβ/AEP activation cleaves NAMPT, depletes systemic NAD, and drives vascular deterioration, senescence, and shortened lifespan in mice; AEP inhibition or NMN mitigates this, with CP#11A outperforming NMN.
Abstract
Age-related microvascular dysfunction disrupts nutrient homeostasis and waste clearance, leading to organ failure. However, a critical gap remains in our understanding of the specific molecular drivers of vascular deterioration and how they orchestrate organism-wide aging. Here, we identify progressive activation of the CCAAT/enhancer-binding protein β (C/EBPβ)/asparagine endopeptidase (AEP) pathway in aging vascular endothelial cells contributes to vascular degeneration and lifespan reduction. Endothelial-specific C/EBPβ or AEP overexpression accelerated vascular aging and shortened lifespan in mice. Mechanistically, AEP mediates proteolytic cleavage of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in nicotinamide adenine dinucleotide (oxidised form, NAD) biosynthesis, resulting in systemic NADdepletion and senescence that elicits both central and peripheral vascular dysfunction and ultimately systemic aging. Genetic ablation of AEP or expression of AEP-resistant NAMPT N136A mutant significantly ameliorated vascular aging and extended lifespan in endothelial-specific Tie 2-C/EBPβ transgenic mice. Pharmacologically, AEP inhibitor CP#11A or nicotinamide mononucleotide (NMN) supplementation alleviated age-related vascular decline, with CP#11A showing superior efficacy. These findings support a model in which endothelial senescence contributes to vascular dysfunction and systemic aging mediated by C/EBPβ/AEP signaling, and establish C/EBPβ/AEP as a therapeutic target to preserve vascular integrity and mitigate systemic frailty in aging populations.
Why this matters
Most NAD-in-aging narratives frame the decline as gradual transcriptional loss of NAMPT or elevated CD38 consumption, positioning NMN/NR precursors as the natural corrective. This finding replaces that with a proteolytic collapse model — endothelial C/EBPβ induces AEP, which physically cleaves NAMPT — and reports that an AEP inhibitor (CP#11A) outperforms NMN in mice, which reframes the endothelium as the systemic NAD-controlling organ and puts precursor-supplementation strategies in competition with upstream protease inhibition.